logo
Select company
Select metric
Ticker Information

Ticker

ENTA

Company Name

ENANTA PHARMACEUTICALS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

ENANTA PHARMACEUTICALS INC - Capital Expenditures to Operating Cash Flow Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

ENTA - CapEx/OCF Historical data
DateCapital ExpenditureCapital Expenditures to Operating Cash FlowNet Cash Flow - Operations
6/30/2025$ 20.39M0%$ -23.18M
3/31/2025$ 26.78M0%$ -55.46M
12/31/2024$ 25.91M0%$ -70.58M
9/30/2024$ 17.95M0%$ -78.76M
6/30/2024$ 10.37M0%$ -89.97M
3/31/2024$ 5.97M0%$ -107.32M
12/31/2023$ 6.69M0%$ -92.5M
9/30/2023$ 9.06M0%$ -103.15M
6/30/2023$ 9.13M0%$ -97.09M
3/31/2023$ 7.23M0%$ -94.56M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • ENANTA PHARMACEUTICALS INC's latest trailing twelve months (TTM) CapEx/OCF stands at 20.39%.
  • Over the past 5 years, ENANTA PHARMACEUTICALS INC's average CapEx/OCF has been 20.39%.
  • The median CapEx/OCF for ENANTA PHARMACEUTICALS INC during this period was 20.39%
  • ENANTA PHARMACEUTICALS INC reached its highest CapEx/OCF over the past 5 years at 20.39%.
  • The lowest CapEx/OCF recorded by ENANTA PHARMACEUTICALS INC in the same timeframe 20.39%

ENANTA PHARMACEUTICALS INC's CapEx/OCF vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

CapEx/OCF Benchmarks
CompanyCapEx/OCF
THTX : THERATECHNOLOGIES INC 0.16%BDTX : BLACK DIAMOND THERAPEUTICS INC -PLX : PROTALIX BIOTHERAPEUTICS INC -ALEC : ALECTOR INC -SGMO : SANGAMO THERAPEUTICS INC -CSBR : CHAMPIONS ONCOLOGY INC 5.67%SPRO : SPERO THERAPEUTICS INC -CCCC : C4 THERAPEUTICS INC -TRDA : ENTRADA THERAPEUTICS INC -CELU : CELULARITY INC -

Definition of Capital Expenditures to Operating Cash Flow

[Calculation] The CapEx to Operating Cash Flow ratio, measures how much of a company’s operating cash flow is reinvested into productive [Assets]. It is capital expenditures [CapEx] divided by net operating cash flow [NCFO].
CapEx / CF - Operations
(=) CapEx/OCF
CapEx/OCF for ENANTA PHARMACEUTICALS INC is calculated as follows: CapEx [ $ 1.45M ] / CF - Operations [ $ 7.09M ]
(=) CapEx/OCF [ 20.39% ]

ENTA - Capital Expenditures to Operating Cash Flow, Last 5 years

20.39%

Minimum

Sep 30, 2020

20.39%

Maximum

Sep 30, 2020

20.39%

Average

20.39%

Median

CapEx/OCF Benchmark Analysis

The chart above depicts the distribution of CapEx/OCF for companies in the Total Stock Market. The average CapEx/OCF of the companies is 31.82% with a standard deviation of 29.52%.
The following table provides additional summary stats:
CapEx/OCF in the Market:
filtered constituents2.35K
min0.01%
max128%
average31.82%
median22.42%
std29.52%